<SEC-DOCUMENT>0001178913-25-003546.txt : 20251023
<SEC-HEADER>0001178913-25-003546.hdr.sgml : 20251023
<ACCEPTANCE-DATETIME>20251023060257
ACCESSION NUMBER:		0001178913-25-003546
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20251023
DATE AS OF CHANGE:		20251023

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93797
		FILM NUMBER:		251411275

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SPHERA FUNDS MANAGEMENT LTD.
		CENTRAL INDEX KEY:			0001496201
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		4 ITZHAK SADE BUILDING A
		STREET 2:		29TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6777520
		BUSINESS PHONE:		972-3-6845535

	MAIL ADDRESS:	
		STREET 1:		4 ITZHAK SADE BUILDING A
		STREET 2:		29TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6777520
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>SCHEDULE 13G/A</submissionType>
<previousAccessionNumber>0001178913-24-000359</previousAccessionNumber>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001496201</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<amendmentNo>2</amendmentNo>
<securitiesClassTitle>Common Shares, no par value per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>09/30/2025</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001374339</issuerCik>
<issuerName>ProMIS Neurosciences Inc.</issuerName>
<issuerCusip>74346M406</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<com:street1>Suite 200, 1920 Yonge Street</com:street1>
<com:city>Toronto</com:city>
<com:stateOrCountry>A6</com:stateOrCountry>
<com:zipCode>M4S 3E2</com:zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Sphera Funds Management Ltd.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>3122090</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>3122090</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3122090</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.51</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Percentage reported in Item 11 is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Sphera Global Healthcare GP Ltd.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>3122090</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>3122090</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3122090</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.51</classPercent>
<typeOfReportingPerson>CO</typeOfReportingPerson>
<comments>Percentage reported in Item 11 is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.</comments>
</coverPageHeaderReportingPersonDetails>
<coverPageHeaderReportingPersonDetails>

<reportingPersonName>Sphera Global Healthcare Management LP.</reportingPersonName>
<memberGroup>b</memberGroup>
<citizenshipOrOrganization>L3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>0</soleVotingPower>
<sharedVotingPower>3122090</sharedVotingPower>
<soleDispositivePower>0</soleDispositivePower>
<sharedDispositivePower>3122090</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3122090</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.51</classPercent>
<typeOfReportingPerson>PN</typeOfReportingPerson>
<comments>Percentage reported in Item 11 is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.</comments>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>ProMIS Neurosciences Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>Suite 200, 1920 Yonge Street, Toronto, Ontario, Canada, M4S 3E2</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>Sphera Funds Management Ltd.&#13;
Sphera Global Healthcare GP Ltd.&#13;
Sphera Global Healthcare Management LP</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>Address of the Principal Business Office of each of the reporting persons is: 4 Itzhak Sade, Building A, 29th Floor, Tel Aviv 6777504, Israel</principalBusinessOfficeOrResidenceAddress>
<citizenship>Each of the reporting person is organized under the laws of the State of Israel</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>See row 9 of cover page of each reporting person. &#13;
		&#13;
The securities reported herein by Sphera Funds Management Ltd., Sphera Global Healthcare GP Ltd. and Sphera Global Healthcare Management LP are beneficially owned as follows:&#13;
&#13;
*	511,875 warrants, with each warrant currently exercisable into one Common Share, representing a total of 0.90% of the total Common Shares outstanding are held directly by Sphera Global Healthcare Master Fund, which has delegated its investment management authority to Sphera Global Healthcare Management LP (the "Management Company").&#13;
&#13;
*	295,187 Common Shares and 2,315,028 warrants, with each warrant currently exercisable into one Common Share, together representing a total of 4.61% of the total Common Shares outstanding, are held directly by Sphera Biotech Master Fund, L.P., which has delegated its investment management authority to the Management Company.&#13;
&#13;
The Management Company is managed, controlled, and operated by its general partner, Sphera Global Healthcare GP Ltd., the shares of which are owned 90% by Sphera Funds Management Ltd. &#13;
	&#13;
This Statement shall not be construed as an admission by any of the Reporting Persons that it is the beneficial owner of any of the securities covered by this Statement, and each Reporting Person disclaims beneficial ownership of any such securities. In addition, the Reporting Persons and other entities named in this Schedule 13G may be deemed to constitute a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that a group exists for purposes of Section 13(d) of the Securities Exchange Act of 1934 or for any other purpose, and each of the Reporting Persons and other entities named in this Schedule 13G disclaims the existence of any such group.</amountBeneficiallyOwned>
<classPercent>Incorporated by reference to Item 11 of the cover page for each reporting person.&#13;
&#13;
Percentage reported in Item 11 for each reporting person is based on 53,811,110 Common Shares outstanding as of September 26, 2025 (as provided by the Issuer in its Definitive Proxy Statement on Schedule 14A filed with the SEC on October 3, 2025) and 2,826,903 warrants beneficially owned by the Reporting Persons as described in Item 4(a), with each warrant currently exercisable into one Common Share.</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>Incorporated by reference to Item 5 of the cover page for each reporting person.</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>Incorporated by reference to Item 6 of the cover page for each reporting person. See also note in Item 4(a) above.</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>Incorporated by reference to Item 7 of the cover page for each reporting person.</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>Incorporated by reference to Item 8 of the cover page for each reporting person. See also note in Item 4(a) above.</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>Y</notApplicableFlag>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
</item10>
</items>
<exhibitInfo>Exhibit 1: Joint Filing Agreement by and among the reporting persons (incorporated herein by reference to Exhibit 1 to the Schedule 13G filed on August 30, 2023)</exhibitInfo>
<signatureInformation>
<reportingPersonName>Sphera Funds Management Ltd.</reportingPersonName>
<signatureDetails>
<signature>/s/ Adi Hanetz</signature>
<title>Adi Hanetz / General Counsel</title>
<date>10/23/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Sphera Global Healthcare GP Ltd.</reportingPersonName>
<signatureDetails>
<signature>/s/ Adi Hanetz</signature>
<title>Adi Hanetz / General Counsel</title>
<date>10/23/2025</date>
</signatureDetails>
</signatureInformation>
<signatureInformation>
<reportingPersonName>Sphera Global Healthcare Management LP.</reportingPersonName>
<signatureDetails>
<signature>/s/ Adi Hanetz</signature>
<title>Adi Hanetz / General Counsel</title>
<date>10/23/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
